Literature DB >> 20581736

Prospective characterization of norovirus compared with rotavirus acute diarrhea episodes in chilean children.

Miguel L O'Ryan1, Alfredo Peña, Rodrigo Vergara, Janepsy Díaz, Nora Mamani, Hector Cortés, Yalda Lucero, Roberto Vidal, Gonzalo Osorio, María Elena Santolaya, Germán Hermosilla, Valeria J Prado.   

Abstract

BACKGROUND: Rotavirus and more recently noroviruses are recognized as main causes of moderate to severe acute diarrhea episodes (ADE) in children < or =5 years of age. Comparing epidemiologic and clinical features of norovirus to rotavirus ADE will aid in the decision-making process required to develop norovirus vaccines.
METHODS: Surveillance for ADE occurring in children < or =5 years of age was implemented in the emergency department (ED) and ward of a large hospital in Santiago and Valparaiso, and in 4 outpatient clinics in Santiago. A stool sample was obtained within 48 hours of consultation for rotavirus detection by enzyme-linked immunosorbent assay and noroviruses by enzyme-linked immunosorbent assay or reverse transcription polymerase chain reaction. For ED and hospital rotavirus and norovirus ADE parents were instructed to monitor clinical findings associated with severity until the end of the episode. The 20-point Vesikari score was used to determine disease severity.
RESULTS: Between July 2006 and October 2008 rotavirus and noroviruses were detected in 331 (26%) and 224 (18%) of 1913 ADE evaluated. The proportion of rotavirus-positive samples in hospital ward, ED, and outpatient clinic was 40%, 26% to 30%, and 13% compared with 18%, 17% to 19%, and 14% for noroviruses. Mean age and 25%-75% interquartile interval of children with rotavirus and norovirus ADE were remarkably similar, 15.6 months (9-20), and 15.5 months (9-19), respectively. Rotavirus cases displayed an autumn-winter peak followed 2 to 3 months later by the norovirus peak. The mean (interquartile) for the Vesikari score was 12.9 (11-15) and 11.9 (9-14.5) for rotavirus (N = 331) and norovirus (N = 224) ADE, respectively, P = 0.003. Compared with norovirus, rotavirus ADE were more common in the 11 to 16 severity score interval (P = 0.006), had a higher maximum stool output in a given day (P = 0.01) and more frequent fever (P < 0.0001). Duration of diarrhea, presence, duration and intensity of vomiting, and intensity of fever did not differ between viruses. Mixed rotavirus and norovirus infections were uncommon (<1%) and not clinically more severe. Clinical severity of ADE in young infants was similar for rotavirus and lower (P = 0.03) for noroviruses compared with older children.
CONCLUSION: Noroviruses are a significant cause of moderate to severe endemic ADE in Chilean children. Although significantly less severe than rotavirus as a group, most norovirus episodes were moderate to severe clinically. An effective norovirus vaccine would be of significant additional benefit to the current rotavirus vaccine in decreasing disease burden associated with ADE.

Entities:  

Mesh:

Year:  2010        PMID: 20581736     DOI: 10.1097/INF.0b013e3181e8b346

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  15 in total

Review 1.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Viral pathogens of acute gastroenteritis in Egyptian children: role of the parechovirus.

Authors:  Mervat El-Sayed Mashaly; Nashwa M Alkasaby; Asmaa Bakr; Maysaa El Sayed Zaki; Karim Montasser
Journal:  BMC Infect Dis       Date:  2022-06-29       Impact factor: 3.667

3.  Prevalence and genetic diversity of norovirus among patients with acute diarrhea in Guatemala.

Authors:  Alejandra Estévez; Wences Arvelo; Aron J Hall; María R López; Beatriz López; Lissette Reyes; Juan Carlos Moir; Nicole Gregoricus; Jan Vinjé; Umesh D Parashar; Kim A Lindblade
Journal:  J Med Virol       Date:  2013-04-17       Impact factor: 2.327

Review 4.  The burden of norovirus gastroenteritis: an important foodborne and healthcare-related infection.

Authors:  G Belliot; B A Lopman; K Ambert-Balay; P Pothier
Journal:  Clin Microbiol Infect       Date:  2014-08       Impact factor: 8.067

5.  Clinical characteristics and outcome in norovirus gastroenteritis.

Authors:  Min-Sho Ku; Ji-Nan Sheu; Ching-Pin Lin; Yu-Hua Chao; Shan-Ming Chen
Journal:  Indian J Pediatr       Date:  2014-04-06       Impact factor: 1.967

Review 6.  Norovirus vaccines: Correlates of protection, challenges and limitations.

Authors:  Nada M Melhem
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

7.  Cost-effectiveness of norovirus vaccination in children in Peru.

Authors:  Andrew J Mirelman; Sarah Blythe Ballard; Mayuko Saito; Margaret N Kosek; Robert H Gilman
Journal:  Vaccine       Date:  2015-05-15       Impact factor: 3.641

8.  Epidemiological and molecular features of norovirus infections in Italian children affected with acute gastroenteritis.

Authors:  M C Medici; F Tummolo; V Martella; C Chezzi; M C Arcangeletti; F De Conto; A Calderaro
Journal:  Epidemiol Infect       Date:  2014-01-20       Impact factor: 4.434

9.  The Changing Landscape of Pediatric Viral Enteropathogens in the Post-Rotavirus Vaccine Era.

Authors:  Natasha Halasa; Bhinnata Piya; Laura S Stewart; Herdi Rahman; Daniel C Payne; Amy Woron; Linda Thomas; Lisha Constantine-Renna; Katie Garman; Rendie McHenry; James Chappell; Andrew J Spieker; Christopher Fonnesbeck; Einas Batarseh; Lubna Hamdan; Mary E Wikswo; Umesh Parashar; Michael D Bowen; Jan Vinjé; Aron J Hall; John R Dunn
Journal:  Clin Infect Dis       Date:  2021-02-16       Impact factor: 9.079

Review 10.  Tropical and travel-associated norovirus: current concepts.

Authors:  Sarah-Blythe Ballard; Mayuko Saito; Andrew J Mirelman; Caryn Bern; Robert H Gilman
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.